Helicobacter pylori infection
Conditions
Interventions
LBTM group:lansoprazol 30mg bid + colloidal bismuth 150mg tid + tetracycline 0.5 tid + metronidazole 0.4 tid ,14 days
VT group:vonoprazan 20mg bid + tetracycline 0.5g tid, 14 days
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age range from 18 to 70 years old, regardless of gender; 2. Chronic gastritis patients who are positive for Helicobacter pylori (? HP positive refers to those who have tested positive for urea breath test within one month before enrollment; ? Chronic gastritis refers to those who have been diagnosed through gastroscopy within three months before enrollment); 3. Penicillin is not allergic and has not received Helicobacter pylori eradication treatment in the past (initial treatment); 4. Patients with normal liver, kidney, and heart functions; 5. Those who agree to participate in this experiment and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those who have used antibiotics, bismuth or PPI within 4 weeks before treatment; 2. Pregnant or lactating women; 3. Patients with other serious diseases that may affect the evaluation of this study, such as severe liver disease, heart disease, kidney disease, malignant tumors, or alcoholism; 4. Individuals who are allergic to the drugs or their components used in this study; 5. Participated in other drug studies within 3 months prior to using the investigational drug; 6. Gastroscopy indicates that in addition to gastritis, there are also cases of gastric ulcers and/or duodenal ulcers, or reflux esophagitis, and other conditions where PPI or bismuth must continue to be taken after eradicating Helicobacter pylori; 7. Patients are unable to express their complaints correctly, such as mental illness or severe neurosis, and cannot cooperate with the participants in this trial; 8. Other situations that the researcher deems unsuitable for participation in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| successfual eradication; | — |
Secondary
| Measure | Time frame |
|---|---|
| prevalence of side effects; | — |
Countries
China
Contacts
Public ContactWen Gao
Peking University First Hospital
Outcome results
None listed